HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide

Subscribe to New Research on N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide

Sch-503034 is the (1R,2S,5S)-isomer; an HCV protease inhibitor; structure in first source

Also Known As:

Sch 503034; Sch-503034; Sch503034; boceprevir

Networked: 369 relevant articles (51 outcomes, 65 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10808
  - Cyclic Amino Acids: 3
    - Imino Acids: 9
      - Proline: 2045
        N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide: 369

Experts

1.	Poordad, Fred: 13 articles (05/2014 - 03/2011)
2.	Brass, Clifford A: 13 articles (05/2014 - 08/2010)
3.	Bronowicki, Jean-Pierre: 12 articles (09/2015 - 03/2011)
4.	Albrecht, Janice K: 12 articles (05/2014 - 08/2010)
5.	Pedicone, Lisa D: 11 articles (05/2014 - 08/2010)
6.	Sulkowski, Mark S: 10 articles (05/2014 - 03/2011)
7.	Zeuzem, Stefan: 10 articles (11/2013 - 04/2007)
8.	Hézode, Christophe: 9 articles (09/2015 - 01/2012)
9.	Gordon, Stuart C: 9 articles (09/2015 - 08/2010)
10.	Jacobson, Ira M: 9 articles (08/2014 - 08/2010)

Related Diseases

1.	Infection 06/01/2015 - "Boceprevir is no longer widely used in the US or EU due to the introduction of second-generation treatments for HCV infection. " 06/01/2015 - "Boceprevir (BOC) is a directly-acting antiviral agent for the treatment of hepatitis C virus genotype 1 (HCV-1) infection. " 01/01/2015 - "The durability of sustained virologic response (SVR) following boceprevir-based therapy in patients with hepatitis C virus (HCV) infection has not been reported. " 02/01/2014 - "How to optimize current therapy of HCV genotype 1 infection with boceprevir." 11/01/2013 - "Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. "
2.	Chronic Hepatitis C 02/01/2013 - "This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. " 03/15/2015 - "A 55-year-old woman was started on boceprevir (800 mg orally thrice daily) during week 5 of triple therapy for chronic hepatitis C. " 01/01/2015 - "Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia." 01/01/2015 - "Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C." 10/01/2014 - "In untreated genotype 1b chronic hepatitis C patients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy."
3.	Hepatitis C 03/01/2013 - "Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs. " 01/01/2013 - "The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. " 10/01/2015 - "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease." 10/01/2014 - "Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV." 08/01/2014 - "In this real-world cohort, 49% of patients stopped boceprevir-based hepatitis C therapy early, with only 20% stopping due to treatment futility. "
4.	Fibrosis (Cirrhosis) 07/28/2015 - "Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers." 04/01/2015 - "SVR rates were 31% (95% CI: 24-40) and 50% (95% CI: 44-56) in boceprevir patients with and without cirrhosis, respectively. " 01/01/2015 - "Boceprevir in combination with P/R achieved fairly good SVR rates in patients that were"most difficult to treat"who failed on dual therapy and was effective among patients with cirrhosis." 11/28/2014 - "Boceprevir obtained high SVR response independent of previous response, RVR or baseline fibrosis or cirrhosis. " 03/01/2014 - "A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis."
5.	Anemia 01/01/2012 - "Anemia, the most frequent adverse event related to administration of boceprevir, occurred in about 50% of patients. " 03/31/2011 - "Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. " 02/01/2012 - "The most common adverse events with boceprevir included anemia and dysgeusia. " 05/01/2015 - "Anemia is a well-known RBV-related event in HCV therapy which is exacerbated by the addition of telaprevir and boceprevir. " 01/01/2015 - "In terms of safety, the risks of anemia and discontinuations due to AEs were lower for simeprevir compared to PR alone, telaprevir, and boceprevir. "

Related Drugs and Biologics

1.	telaprevir
2.	Ribavirin (Virazole)
3.	Protease Inhibitors (Protease Inhibitor)
4.	Interferons
5.	Antiviral Agents (Antivirals)
6.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
7.	peginterferon alfa-2b (Pegintron)
8.	Interferon-alpha (Interferon Alfa)
9.	RNA (Ribonucleic Acid)
10.	MK-7009

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Liver Transplantation
3.	Transplantation (Transplant Recipients)
4.	Individualized Medicine
5.	Highly Active Antiretroviral Therapy (HAART)